Seeking Alpha

Elan (ELN +7.6%) shares see notable strength following positive comments on the potential of the...

Elan (ELN +7.6%) shares see notable strength following positive comments on the potential of the company's Alzheimer's drug Bapineuzumab: The FDA is signalling "they will be very reasonable about getting something to patients that has a modicum of benefit," Chairman Robert Ingram says. Also goosing shares is mention of ELN as a takeover target: "If an offer comes, we can't ignore it..."
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs